Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.

  • Revenue in USD (TTM)37.64bn
  • Net income in USD4.19bn
  • Incorporated1999
  • Employees90.10k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 208 047 5000
  • Fax+44 208 047 7807
  • Websitehttps://www.gsk.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GSK:LSE since
Affinivax IncDeal completed31 May 202231 May 2022Deal completed-33.95%3.30bn
Sierra Oncology IncDeal completed13 Apr 202213 Apr 2022Deal completed-36.02%2.08bn
Data delayed at least 20 minutes, as of Nov 29 2022 15:57 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
DuPont de Nemours Inc14.18bn1.16bn34.45bn28.00k30.301.3813.832.432.293.6327.8450.150.31483.545.49506,571.402.71-0.22273.11-0.289235.0531.608.62-1.611.995.110.3173--16.15-19.13172.14-15.09-25.20-26.30
Iqvia Holdings Inc14.31bn1.18bn39.83bn83.00k34.907.4517.882.786.156.1574.4328.780.593--5.76181,101.304.941.776.252.1434.7234.308.343.64--5.190.69860.0022.1415.28246.2468.0831.30--
Moderna Inc21.39bn11.77bn67.38bn2.70k6.343.775.563.1527.6527.6550.6946.490.91062.937.337,922,222.0050.0941.1777.8866.7879.20--55.0052.351.80--0.05990.002,199.12179.441,733.33--53.67--
GSK plc (ADR)37.64bn4.19bn68.61bn90.10k14.23--8.341.822.378.4420.64--0.45292.004.14417,752.306.086.969.4211.6165.4168.4813.4314.680.74410.200.717394.850.0444.11-23.7336.904.50--
Zoetis Inc8.01bn2.07bn69.04bn12.10k33.8614.8227.328.624.384.3816.9410.000.58491.146.84661,735.6015.0813.7917.9316.0470.1968.7525.7823.941.4812.190.584722.5316.499.7324.3619.9317.1720.72
Regeneron Pharmaceuticals Inc13.71bn5.37bn80.75bn10.37k15.643.7614.165.8947.4047.40120.98197.050.5340.89672.491,322,357.0020.9225.6424.0029.9985.3988.5139.1739.114.5220.540.1119--89.1427.02129.8655.241.52--
Vertex Pharmaceuticals Incorporated8.70bn3.27bn80.93bn3.90k24.886.2123.699.3012.6712.6733.6950.770.59342.897.002,230,913.0022.3218.0126.4021.8788.0087.7737.6229.174.5532.160.03280.0022.0634.79-13.63--32.96--
Data as of Nov 29 2022. Currency figures normalised to GSK plc's reporting currency: US Dollar USD

Institutional shareholders

6.90%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 30 Sep 202258.58m2.88%
Fisher Asset Management LLCas of 30 Sep 202212.17m0.60%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 202211.18m0.55%
Capital Research & Management Co. (International Investors)as of 30 Sep 202211.07m0.54%
Renaissance Technologies LLCas of 30 Sep 20229.35m0.46%
Arrowstreet Capital LPas of 30 Sep 20228.05m0.40%
Goldman Sachs Asset Management LPas of 30 Sep 20227.63m0.38%
Fidelity Management & Research Co. LLCas of 30 Sep 20227.58m0.37%
SSgA Funds Management, Inc.as of 30 Sep 20227.57m0.37%
Two Sigma Investments LPas of 30 Sep 20227.14m0.35%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.